Status:
COMPLETED
HPV Vaccine Intervention for Young Sexual Minority Men
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Healthy Subject
Eligibility:
MALE
18-25 years
Phase:
NA
Brief Summary
This phase III trial studies how well the Outsmart HPV intervention works in increasing HPV vaccine initiation and completion among young individuals who report having a history of same-sex partners, ...
Detailed Description
PRIMARY OBJECTIVES: I. Determine the efficacy of the Outsmart HPV intervention on increasing HPV vaccine initiation and completion. II. Identify mediators that explain the relationship between study...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Cisgender male
- Ages 18-25
- Sexual minority (reports ever having oral or anal sex with a male or being sexually attracted to males; or identifies as gay, bisexual, or queer)
- Lives in the United States (US)
- Has not received any doses of HPV vaccine
- Did not participate in the pilot study
- Read English
- Able to provide informed consent (inferred by completing the screener survey and consent form)
Exclusion
Key Trial Info
Start Date :
October 3 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2022
Estimated Enrollment :
1227 Patients enrolled
Trial Details
Trial ID
NCT04032106
Start Date
October 3 2019
End Date
March 31 2022
Last Update
March 14 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Minnesota
Minneapolis, Minnesota, United States, 55455
2
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210